Recent Finacing
Recent Raise
Clinical-stage ophthalmology biotech developing intravitreal therapies, including Restoret (tri-specific Wnt agonist); conducting AMARONE Phase 1b/2a with MAD enrollment, targeting DME and nAMD; operations in US and UK.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Eyebiotech.
